Hunan Warrant Pharmaceutical Co. Ltd. A

688799 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

46.58CNY-6.42 (-12.11%)

Price History

Full chart

Market Stats

Previous Close53.00

Open52.47

Day Range46.03 – 52.98

52-Week Range40.33 – 64.94

Volume9.79M

Market Cap7.65B

P/E (TTM)33.26

Forward P/E0.00

EPS1.72

Dividend Yield0.31%

Beta0.19

50-Day Avg47.82

200-Day Avg49.85

About

Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products in China. It offers medicines in the areas of digestive, respiratory, anti-infective, diabetes, Hypertension, calcium supplementation cardiovascular, cerebrovascular, and other fields. The company also provides APIs and Intermediates. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Ben Dong Huang
Employees1.33K
HeadquartersBuilding C6-C7, Changsha, China, 410006, China
Websitehttps://www.warrant.com.cn

Leadership

Mr. Ben Dong HuangChairman & GM · b. 1964
Ms. Gui Ying WuFinancial Director & Accounting Supervisor · b. 1981
Mr. Xiang GaoDirector & Deputy GM · b. 1971
Mr. Qiao QiaoSecretary to the Board · b. 1991
Ms. Dou LinDeputy General Manager · b. 1976
Mr. Zhigang ZhouDeputy General Manager · b. 1980
Mr. Jian XiaoDeputy General Manager · b. 1982
Mr. Yue TanCore Technical Staff · b. 1982
Mr. Xiaoguang ChenExecutive Officer · b. 1983

Financials

Income Statement

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	193.57M	246.80M	255.63M	374.87M	613.25M	824.65M	950.63M	1.15B	1.29B	1.43B	1.41B	1.52B
Growth (%)	-	+27.50%	+3.58%	+46.65%	+63.59%	+34.47%	+15.28%	+20.61%	+12.74%	+10.84%	-1.38%	+7.26%
Cost of Revenue	99.00M	131.54M	138.44M	154.96M	186.41M	246.68M	262.39M	319.33M	421.91M	512.15M	547.62M	597.40M
Gross Profit	94.58M	115.26M	117.19M	219.92M	426.84M	577.97M	688.24M	827.26M	870.75M	920.64M	865.33M	1.52B
Gross Margin	48.86%	46.70%	45.84%	58.66%	69.60%	70.09%	72.40%	72.15%	67.36%	64.26%	61.24%	100.00%
Operating Expense	75.12M	87.02M	98.02M	163.89M	322.61M	450.24M	527.36M	645.37M	674.75M	683.53M	703.57M	1.27B
Operating Income	19.46M	28.24M	19.17M	56.03M	104.23M	127.73M	160.88M	181.89M	196.00M	237.11M	161.77M	245.13M
Operating Margin	10.05%	11.44%	7.50%	14.95%	17.00%	15.49%	16.92%	15.86%	15.16%	16.55%	11.45%	16.17%
EBITDA	31.86M	44.27M	30.01M	92.68M	128.17M	153.88M	194.20M	214.42M	243.91M	291.02M	230.60M	314.45M
EBITDA Margin	16.46%	17.94%	11.74%	24.72%	20.90%	18.66%	20.43%	18.70%	18.87%	20.31%	16.32%	20.75%
Net Income	20.85M	27.88M	18.76M	59.76M	88.49M	116.01M	145.03M	160.76M	182.80M	211.32M	164.32M	241.47M
Net Income Margin	10.77%	11.30%	7.34%	15.94%	14.43%	14.07%	15.26%	14.02%	14.14%	14.75%	11.63%	15.93%
R&D	20.33M	15.80M	16.30M	15.20M	25.62M	45.43M	63.66M	70.06M	88.67M	103.18M	160.97M	129.85M
R&D as % of Total Revenue	10.50%	6.40%	6.38%	4.05%	4.18%	5.51%	6.70%	6.11%	6.86%	7.20%	11.39%	8.57%
Interest Expense	3.00M	1.38M	-	2.13M	696.77K	36.96K	50.95K	166.51K	163.17K	120.09K	17.21K	647.37K
Interest Expense % of Total Revenue	1.55%	0.56%	-	0.57%	0.11%	0.00%	0.01%	0.01%	0.01%	0.01%	0.00%	0.04%

Balance Sheet

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	250.74M	406.15M	390.01M	626.32M	732.02M	851.44M	921.12M	1.80B	2.01B	2.18B	2.46B	3.05B
Total Liabilities	92.29M	141.12M	103.33M	242.50M	273.77M	298.27M	258.07M	318.07M	350.35M	408.70M	637.06M	1.01B
Total Equity	128.69M	236.57M	286.68M	383.82M	458.25M	553.17M	663.05M	1.48B	1.60B	1.72B	1.80B	2.04B
Cash	11.42M	76.68M	6.81M	39.79M	19.62M	70.93M	79.02M	353.39M	191.29M	379.65M	177.74M	203.78M
Total Debt	30.80M	20.00M	20.00M	40.00M	500.00K	19.80M	11.77M	6.83M	13.12M	17.12M	117.70M	-
Net Debt	19.38M	-56.68M	13.19M	212.89K	-19.12M	-51.13M	-67.25M	-346.56M	-178.17M	-362.53M	-60.04M	293.83M

Cash Flow

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	22.73M	37.48M	11.32M	56.25M	64.80M	116.66M	104.66M	114.72M	155.65M	214.44M	142.23M	300.20M
Investing Cash Flow	-36.89M	-47.28M	-103.09M	-37.62M	-40.01M	-25.21M	-61.14M	-517.30M	-230.62M	39.12M	-358.82M	-
Financing Cash Flow	13.93M	70.49M	25.86M	7.92M	-40.22M	-35.66M	-35.15M	655.65M	-76.37M	-57.47M	14.26M	-
Capital Expenditure	28.53M	82.54M	107.62M	37.62M	35.37M	24.34M	53.75M	92.10M	131.85M	105.76M	233.87M	520.32M
Free Cash Flow	-5.80M	-45.05M	-96.30M	18.62M	29.43M	92.32M	50.91M	22.63M	23.80M	108.68M	-91.65M	-220.12M
Dividends Paid	2.47M	2.58M	1.46M	2.08M	721.85K	35.16M	35.15M	-	65.66M	84.42M	86.35M	62.96M
FCF to OCF	-25.54%	-120.21%	-851.05%	33.11%	45.42%	79.14%	48.64%	19.72%	15.29%	50.68%	-64.44%	-73.32%
Dividend Paid to FCF	-42.64%	-5.72%	-1.52%	11.19%	2.45%	38.09%	69.05%	-	275.92%	77.68%	-94.22%	-28.60%

Earnings

Report Date	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023
EPS Estimate	-	-	-	-	-	-	-
EPS Actual	0.36	0.61	0.36	0.53	0.43	0.63	0.53
Surprise	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap7.65B

Enterprise Value8.25B

Trailing P/E33.26

Forward P/E0.00

Price / Sales5.27

Price / Book3.65

EPS1.72

Book Value15.89

Revenue (TTM)1.45B

Gross Profit (TTM)844.95M

EBITDA231.55M

Profit Margin15.97%

Operating Margin11.27%

Return on Equity11.58%

Return on Assets3.30%

Shares Outstanding133.64M

Shares Float62.47M

Beta0.19

Dividend Yield0.31%

Dividend Rate0.18

Payout Ratio10.40%

Dividends

20261×

0.18Jul 1, 2026

20251×

0.43May 29, 2025

20241×

0.64Oct 25, 2024

20231×

0.64Oct 19, 2023

20221×

0.50May 18, 2022

Stock Splits

May 29, 20251.4:1